TY - JOUR
T1 - Effect of CT fluoroscopy-guided transpulmonary radiofrequency ablation of liver tumours on the lung
AU - Iguchi, T.
AU - Inoue, D.
AU - Yabushita, K.
AU - Sakaguchi, K.
AU - Tatsukawa, M.
AU - Sasaki, H.
AU - Kanazawa, Susumu
PY - 2012/8
Y1 - 2012/8
N2 - Objective: We retrospectively evaluated the effect of transpulmonary radiofrequency ablation (RFA) of liver tumours on the lung. Methods: 16 patients (10 males and 6 females; mean age, 65.2 years) with 16 liver tumours (mean diameter 1.5 cm) underwent transpulmonary RFA under CT fluoroscopic guidance. The tumours were either hepatocellular carcinoma (n=14) or liver metastasis (n=12). All 16 liver tumours were undetectable with ultrasonography. The pulmonary function values at 3 months after transpulmonary RFA were compared with baseline (i.e. values before RFA). Results: In 8 of 16 sessions, minor pulmonary complications occurred, including small pneumothorax (n=8) and small pleural effusion (n=1). In two sessions, major pulmonary complications occurred, including pneumothorax requiring a chest tube (n52). These chest tubes were removed at 4 and 6 days, and these patients were discharged 7 and 10 days after RFA, respectively, without any sequelae. The pulmonary function values we evaluated were forced expiratory volume in 1 s (FEV1.0) and vital capacity (VC). The mean values of FEV1.0 before and 3 months after RFA were 2.55 l and 2.59 l, respectively; the mean values of VC before and 3 months after RFA were 3.20 l and 3.27 l, respectively. These pulmonary values did not show any significant worsening (p=0.393 and 0.255 for FEV1.0 and VC, respectively). Conclusion: There was no significant lung injury causing a fatal or intractable complication after transpulmonary RFA of liver tumours.
AB - Objective: We retrospectively evaluated the effect of transpulmonary radiofrequency ablation (RFA) of liver tumours on the lung. Methods: 16 patients (10 males and 6 females; mean age, 65.2 years) with 16 liver tumours (mean diameter 1.5 cm) underwent transpulmonary RFA under CT fluoroscopic guidance. The tumours were either hepatocellular carcinoma (n=14) or liver metastasis (n=12). All 16 liver tumours were undetectable with ultrasonography. The pulmonary function values at 3 months after transpulmonary RFA were compared with baseline (i.e. values before RFA). Results: In 8 of 16 sessions, minor pulmonary complications occurred, including small pneumothorax (n=8) and small pleural effusion (n=1). In two sessions, major pulmonary complications occurred, including pneumothorax requiring a chest tube (n52). These chest tubes were removed at 4 and 6 days, and these patients were discharged 7 and 10 days after RFA, respectively, without any sequelae. The pulmonary function values we evaluated were forced expiratory volume in 1 s (FEV1.0) and vital capacity (VC). The mean values of FEV1.0 before and 3 months after RFA were 2.55 l and 2.59 l, respectively; the mean values of VC before and 3 months after RFA were 3.20 l and 3.27 l, respectively. These pulmonary values did not show any significant worsening (p=0.393 and 0.255 for FEV1.0 and VC, respectively). Conclusion: There was no significant lung injury causing a fatal or intractable complication after transpulmonary RFA of liver tumours.
UR - http://www.scopus.com/inward/record.url?scp=84864860896&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864860896&partnerID=8YFLogxK
U2 - 10.1259/bjr/34646739
DO - 10.1259/bjr/34646739
M3 - Article
C2 - 22374277
AN - SCOPUS:84864860896
VL - 85
SP - e373-e377
JO - British Journal of Radiology
JF - British Journal of Radiology
SN - 0007-1285
IS - 1016
ER -